Actinium Pharmaceuticals Inc (STU:7AY1)
€ 1.321 -0.001 (-0.08%) Market Cap: 41.72 Mil Enterprise Value: -31.26 Mil PE Ratio: 0 PB Ratio: 1.15 GF Score: 27/100

Actinium Pharmaceuticals Inc at TD Cowen Inc Radiopharmaceutical Innovation Summit (Virtual) Transcript

Jun 20, 2023 / 05:30PM GMT
Release Date Price: €6.7 (-2.90%)
Boris Peaker
TD Cowen - Analyst

Thanks, everybody, for staying with us today, and we're continuing with the TD Cowen Radiopharmaceutical Innovation Summit. My name is Boris Peaker. I'm one of the biotech analysts here. It's my pleasure to host Sandesh Seth, who is the CEO of Actinium Pharmaceuticals. And just before we get started, I just want to make two reminders. First, if you want to send me questions you can send directly to my e-mail at [email protected] or you can ask directly through the portal. And lastly, this is II voting season and TD Cowen, and I would appreciate your vote in biotech.

So with that, Sandesh, thanks for joining us.

Sandesh Seth
Actinium Pharmaceuticals, Inc. - CEO & Chairman

Thanks for having me, Boris. Pleasure to be here.

Boris Peaker
TD Cowen - Analyst

So, one of the key questions that we often get on Actinium -- is if you could address the name of the company, really because your lead drug is -- uses iodine-131. So if you could say what -- but can you first of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot